| Lymphoma, Follicular

Brukinsa vs Zevalin

Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.
Deep comparison between: Brukinsa vs Zevalin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsZevalin has a higher rate of injection site reactions vs Brukinsa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zevalin but not Brukinsa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Brukinsa
Zevalin
At A Glance
Oral
Once or twice daily
BTK inhibitor
IV infusion
Single course
CD20-directed radioimmunotherapy
Indications
  • Mantle cell lymphoma
  • Waldenstrom Macroglobulinemia
  • Marginal Zone B-Cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Lymphoma, Follicular
  • Lymphoma, Follicular
Dosing
Mantle cell lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 160 mg orally twice daily or 320 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Lymphoma, Follicular 160 mg orally twice daily in combination with obinutuzumab, with or without food, until disease progression or unacceptable toxicity.
Lymphoma, Follicular Day 1: rituximab 250 mg/m2 IV; Day 7, 8, or 9: rituximab 250 mg/m2 IV then Y-90 Zevalin 0.4 mCi/kg IV over 10 minutes (platelets >=150,000/mm3) or 0.3 mCi/kg IV over 10 minutes (platelets 100,000-149,000/mm3, relapsed or refractory); maximum dose 32 mCi; single course.
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Neutrophil count decreased, platelet count decreased, upper respiratory tract infection, hemorrhage, musculoskeletal pain
Serious Hemorrhage, pneumonia, cytopenias, second primary malignancies, cardiac arrhythmias, hepatotoxicity including drug-induced liver injury
Postmarketing Drug-induced liver injury
Most common (>=5%) Cytopenias (thrombocytopenia, neutropenia, anemia, leukopenia, lymphopenia), fatigue, nasopharyngitis, nausea, abdominal pain, asthenia, cough, diarrhea, pyrexia
Serious Prolonged and severe cytopenias (thrombocytopenia, anemia, lymphopenia, neutropenia), MDS/AML, serious infusion reactions, severe cutaneous and mucocutaneous reactions
Postmarketing Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous dermatitis, exfoliative dermatitis, infusion site erythema and ulceration, radiation injury
Pharmacology
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that forms a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK activity and thereby blocking B-cell proliferation, trafficking, chemotaxis, and adhesion pathways driven by B-cell antigen receptor and cytokine receptor signaling.
Ibritumomab tiuxetan is a murine IgG1 kappa monoclonal antibody immunoconjugate that binds specifically to the CD20 antigen on pre-B and mature B lymphocytes and >90% of B-cell NHL; the covalently linked Y-90 chelate (tiuxetan) delivers targeted beta radiation, inducing cellular damage via free radical formation in CD20-expressing and neighboring cells.
View Full FDA Information
View full FDA information
View full FDA information
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Brukinsa
  • Covered on 5 commercial plans
  • PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
View full coverage details ›
No coverage data available for Zevalin.
UnitedHealthcare
Brukinsa
  • Covered on 4 commercial plans
  • PA (5/8) · Step Therapy (5/8) · Qty limit (4/8)
View full coverage details ›
No coverage data available for Zevalin.
Humana
Brukinsa
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
View full coverage details ›
No coverage data available for Zevalin.
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Brukinsa.
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
BrukinsaView full Brukinsa profile
ZevalinView full Zevalin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.